Related Experiment Video

Updated: May 12, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Cardiovascular effects of sphingosine-1-phosphate (S1P)

Bodo Levkau1

  • 1University of Duisburg-Essen, Essen, Germany. bodo.levkau@uni-due.de

Handbook of Experimental Pharmacology
|April 9, 2013
PubMed

Insights

Sphingosine-1-phosphate (S1P) is vital for heart and blood vessel health, influencing cardiovascular diseases. Understanding S1P

Area of Science:

  • Cardiovascular Biology and Medicine
  • Lipid Metabolism
  • Molecular Cardiology

Background:

  • Sphingosine-1-phosphate (S1P) plays a critical role in maintaining cardiac and vascular homeostasis.
  • S1P is implicated in the pathogenesis of major cardiovascular disorders, including coronary artery disease, atherosclerosis, myocardial infarction, and heart failure.
  • Plasma S1P is predominantly bound to high-density lipoproteins (HDL), contributing to HDL's cardioprotective effects.

Purpose of the Study:

  • To review the current understanding of S1P's role in cardiovascular physiology and pathology.
  • To explore the involvement of S1P and its receptors in cardiovascular disease.
  • To highlight the therapeutic potential of S1P-targeting drugs.

Main Methods:

  • Literature review of existing research on S1P in cardiovascular contexts.
  • Analysis of studies investigating S1P's physiological and pathophysiological functions.
  • Examination of clinical data related to S1P modulation and cardiovascular outcomes.

Main Results:

  • S1P is a key regulator of cardiovascular homeostasis.
  • S1P contributes to the development of various cardiovascular diseases.
  • HDL-associated S1P confers significant cardiovascular benefits.

Conclusions:

  • S1P and its receptors are crucial in cardiovascular health and disease.
  • Further research is needed to fully elucidate S1P's complex roles in cardiovascular medicine.
  • S1P-based therapies represent a promising avenue for cardiovascular disease treatment.

More Related Videos

Microperfusion Technique to Investigate Regulation of Microvessel Permeability in Rat Mesentery12:48

Microperfusion Technique to Investigate Regulation of Microvessel Permeability in Rat Mesentery

Published on: September 12, 2015

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...